Chemical Compound Review:
CHEBI:507351 calcium(E,3R,5R)-7-[4-(4- fluorophenyl)-2...
Synonyms:
DNC013454, AKOS015967307, AC1O5M4W, Rosuvastatin calcium
This record was replaced with 6439133.
- Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Gianella, A., Nobili, E., Abbate, M., Zoja, C., Gelosa, P., Mussoni, L., Bellosta, S., Canavesi, M., Rottoli, D., Guerrini, U., Brioschi, M., Banfi, C., Tremoli, E., Remuzzi, G., Sironi, L. Am. J. Pathol. (2007)
- Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. Jones, S.P., Gibson, M.F., Rimmer, D.M., Gibson, T.M., Sharp, B.R., Lefer, D.J. J. Am. Coll. Cardiol. (2002)
- Short-term memory loss associated with rosuvastatin. Galatti, L., Polimeni, G., Salvo, F., Romani, M., Sessa, A., Spina, E. Pharmacotherapy (2006)
- Rosuvastatin: a risk-benefit assessment for intensive lipid lowering. Ferdinand, K.C. Expert opinion on pharmacotherapy. (2005)
- Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. De Hert, M., Kalnicka, D., van Winkel, R., Wampers, M., Hanssens, L., Van Eyck, D., Scheen, A., Peuskens, J. The Journal of clinical psychiatry (2006)
- Comparative pharmacology of rosuvastatin. McTaggart, F. Atherosclerosis. Supplements. (2003)
- Optimizing the pharmacology of statins: characteristics of rosuvastatin. Chapman, M.J., McTaggart, F. Atherosclerosis. Supplements. (2002)
- Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Ho, R.H., Tirona, R.G., Leake, B.F., Glaeser, H., Lee, W., Lemke, C.J., Wang, Y., Kim, R.B. Gastroenterology (2006)
- A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Stalenhoef, A.F., Ballantyne, C.M., Sarti, C., Murin, J., Tonstad, S., Rose, H., Wilpshaar, W. Eur. Heart J. (2005)
- Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Dimitroulakos, J., Lorimer, I.A., Goss, G. Clin. Cancer Res. (2006)
- Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Chen, J., Li, D., Schaefer, R., Mehta, J.L. Atherosclerosis (2006)
- Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Schäfer, A., Fraccarollo, D., Vogt, C., Flierl, U., Hemberger, M., Tas, P., Ertl, G., Bauersachs, J. Biochem. Pharmacol. (2007)
- Rhabdomyolysis associated with pomegranate juice consumption. Sorokin, A.V., Duncan, B., Panetta, R., Thompson, P.D. Am. J. Cardiol. (2006)
- Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. Susic, D., Varagic, J., Ahn, J., Slama, M., Frohlich, E.D. J. Am. Coll. Cardiol. (2003)
- The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Schneck, D.W., Birmingham, B.K., Zalikowski, J.A., Mitchell, P.D., Wang, Y., Martin, P.D., Lasseter, K.C., Brown, C.D., Windass, A.S., Raza, A. Clin. Pharmacol. Ther. (2004)
- Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes. Miersch, S., Sliskovic, I., Raturi, A., Mutus, B. Free Radic. Biol. Med. (2007)
- Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Link, A., Ayadhi, T., B??hm, M., Nickenig, G. Eur. Heart J. (2006)
- Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis. van Oostrom, A.J., Plokker, H.W., van Asbeck, B.S., Rabelink, T.J., van Kessel, K.P., Jansen, E.H., Stehouwer, C.D., Cabezas, M.C. Atherosclerosis (2006)
- Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Nangle, M.R., Cotter, M.A., Cameron, N.E. Diabetes (2003)
- Statins prevent dextrose-induced endothelial barrier dysfunction, possibly through inhibition of superoxide formation. Haas, M.J., Horani, M.H., Parseghian, S.A., Mooradian, A.D. Diabetes (2006)
- Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Simonson, S.G., Raza, A., Martin, P.D., Mitchell, P.D., Jarcho, J.A., Brown, C.D., Windass, A.S., Schneck, D.W. Clin. Pharmacol. Ther. (2004)
- Effect of itraconazole on the pharmacokinetics of rosuvastatin. Cooper, K.J., Martin, P.D., Dane, A.L., Warwick, M.J., Schneck, D.W., Cantarini, M.V. Clin. Pharmacol. Ther. (2003)
- ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Huang, L., Wang, Y., Grimm, S. Drug Metab. Dispos. (2006)
- The effect of fluconazole on the pharmacokinetics of rosuvastatin. Cooper, K.J., Martin, P.D., Dane, A.L., Warwick, M.J., Schneck, D.W., Cantarini, M.V. Eur. J. Clin. Pharmacol. (2002)
- Rosuvastatin. Carswell, C.I., Plosker, G.L., Jarvis, B. Drugs (2002)
- Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Caslake, M.J., Stewart, G., Day, S.P., Daly, E., McTaggart, F., Chapman, M.J., Durrington, P., Laggner, P., Mackness, M., Pears, J., Packard, C.J. Atherosclerosis (2003)
- Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice. Li, W., Asagami, T., Matsushita, H., Lee, K.H., Tsao, P.S. J. Pharmacol. Exp. Ther. (2005)